share_log

Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) Market Cap Dropped US$60m Last Week; Individual Investors Who Hold 38% Were Hit as Were Institutions

Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) Market Cap Dropped US$60m Last Week; Individual Investors Who Hold 38% Were Hit as Were Institutions

樂團生物醫學控股有限公司”s(納斯達克股票代碼:OBIO)上週市值下降了6000萬美元;持有38%的個人投資者和機構一樣受到打擊
Simply Wall St ·  03/13 20:34

Key Insights

關鍵見解

  • Significant control over Orchestra BioMed Holdings by retail investors implies that the general public has more power to influence management and governance-related decisions
  • 52% of the business is held by the top 6 shareholders
  • Institutions own 16% of Orchestra BioMed Holdings
  • 散戶投資者對Orchestra BioMed Holdings的嚴格控制意味着公衆擁有更大的影響管理和治理相關決策的權力
  • 52% 的業務由前6名股東持有
  • 機構擁有樂團生物醫學控股公司16%的股份

A look at the shareholders of Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) can tell us which group is most powerful. With 38% stake, retail investors possess the maximum shares in the company. In other words, the group stands to gain the most (or lose the most) from their investment into the company.

看看Orchestra BioMed Holdings, Inc.(納斯達克股票代碼:OBIO)的股東可以告訴我們哪個集團最強大。散戶投資者持有該公司38%的股份,是公司的最大股份。換句話說,該集團將從對公司的投資中獲得最多(或損失最大)。

Following a 24% decrease in the stock price last week, retail investors suffered the most losses, but institutions who own 16% stock also took a hit.

繼上週股價下跌24%之後,散戶投資者遭受的損失最大,但擁有16%股票的機構也受到打擊。

Let's take a closer look to see what the different types of shareholders can tell us about Orchestra BioMed Holdings.

讓我們仔細看看不同類型的股東能告訴我們有關管弦樂團生物醫學控股公司的哪些信息。

ownership-breakdown
NasdaqGM:OBIO Ownership Breakdown March 13th 2024
NasdaqGM:OBIO 所有權明細 2024 年 3 月 13 日

What Does The Institutional Ownership Tell Us About Orchestra BioMed Holdings?

關於管弦樂團生物醫學控股公司,機構所有權告訴我們什麼?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

機構投資者通常將自己的回報與常見指數的回報進行比較。因此,他們通常會考慮收購相關基準指數中包含的大型公司。

Orchestra BioMed Holdings already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Orchestra BioMed Holdings, (below). Of course, keep in mind that there are other factors to consider, too.

樂團生物醫學控股公司已經在股份登記處設立了機構。事實上,他們擁有該公司可觀的股份。這意味着在這些機構工作的分析師已經看過這隻股票,他們很喜歡。但是就像其他人一樣,他們可能錯了。如果兩個大型機構投資者試圖同時拋售股票,股價大幅下跌的情況並不少見。因此,值得查看Orchestra BioMed Holdings過去的收益軌跡(見下文)。當然,請記住,還有其他因素需要考慮。

earnings-and-revenue-growth
NasdaqGM:OBIO Earnings and Revenue Growth March 13th 2024
NasdaqGM:OBIO 收益和收入增長 2024 年 3 月 13 日

It would appear that 16% of Orchestra BioMed Holdings shares are controlled by hedge funds. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. Our data shows that Medtronic plc is the largest shareholder with 16% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 16% and 6.8%, of the shares outstanding, respectively. Additionally, the company's CEO David Hochman directly holds 0.6% of the total shares outstanding.

看來樂團生物醫學控股公司有16%的股票由對沖基金控制。這引起了我的注意,因爲對沖基金有時會試圖影響管理層,或者帶來能夠爲股東創造短期價值的變革。我們的數據顯示,美敦力集團是最大股東,已發行股份的16%。同時,第二和第三大股東分別持有已發行股份的16%和6.8%。此外,該公司首席執行官戴維·霍赫曼直接持有已發行股份總額的0.6%。

We also observed that the top 6 shareholders account for more than half of the share register, with a few smaller shareholders to balance the interests of the larger ones to a certain extent.

我們還觀察到,前六名股東佔股票登記冊的一半以上,少數規模較小的股東可以在一定程度上平衡大股東的利益。

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

雖然研究公司的機構所有權可以爲您的研究增加價值,但研究分析師的建議以更深入地了解股票的預期表現也是一種好做法。有相當數量的分析師在報道該股,因此了解他們對未來的總體看法可能很有用。

Insider Ownership Of Orchestra BioMed Holdings

管弦樂團生物醫學控股公司的內部所有權

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

不同國家對內部人士的定義可能略有不同,但董事會成員總是計算在內。管理層最終向董事會負責。但是,經理成爲執行董事會成員的情況並不少見,特別是如果他們是創始人或首席執行官。

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

我通常認爲內部所有權是一件好事。但是,在某些情況下,這使其他股東更難追究董事會對決策的責任。

Our most recent data indicates that insiders own some shares in Orchestra BioMed Holdings, Inc.. In their own names, insiders own US$3.2m worth of stock in the US$204m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.

我們的最新數據顯示,內部人士擁有Orchestra BioMed Holdings, Inc.的部分股份。內部人士以自己的名義擁有這家價值2.04億美元的公司價值320萬美元的股票。有人會說,這表明股東和董事會之間的利益一致。但是可能值得檢查一下這些內部人士是否一直在出售。

General Public Ownership

一般公有制

The general public-- including retail investors -- own 38% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

包括散戶投資者在內的公衆擁有該公司38%的股份,因此不容忽視。這種所有權規模雖然可觀,但如果決策與其他大股東不同步,可能不足以改變公司政策。

Private Equity Ownership

私募股權所有權

With an ownership of 12%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

私募股權公司擁有12%的所有權,可以在制定以價值創造爲重點的公司戰略方面發揮作用。一些投資者可能會爲此感到鼓舞,因爲私募股權有時能夠鼓勵制定有助於市場看到公司價值的策略。或者,這些持有人可能會在投資上市後退出投資。

Public Company Ownership

上市公司所有權

It appears to us that public companies own 16% of Orchestra BioMed Holdings. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.

在我們看來,上市公司擁有樂團生物醫學控股公司16%的股份。我們無法確定,但這很可能是一個戰略利益。這些企業可能是相似的,也可以是合作的。

Next Steps:

後續步驟:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 4 warning signs for Orchestra BioMed Holdings that you should be aware of.

我覺得看看究竟誰擁有一家公司非常有趣。但是,要真正獲得見解,我們還需要考慮其他信息。例如,我們已經確定了Orchestra BioMed Holdings的4個警告信號,你應該注意這些信號。

Ultimately the future is most important. You can access this free report on analyst forecasts for the company.

歸根結底,未來是最重要的。您可以訪問這份關於公司分析師預測的免費報告。

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

注意:本文中的數字是使用過去十二個月的數據計算得出的,這些數據是指截至財務報表日期當月最後一天的12個月期間。這可能與全年年度報告數據不一致。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論